Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1331 to 1340 of 2733 total matches.
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
earlier for treatment of ulcerative colitis (UC),
plaque psoriasis, and psoriatic arthritis.1 The IL-23 ...
The injectable interleukin (IL)-23 antagonist
guselkumab (Tremfya – Janssen Biotech) has now
been approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults; it was
approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23
antagonists risankizumab (Skyrizi) and mirikizumab
(Omvoh) and the IL-12/23 antagonist ustekinumab
(Stelara, and biosimilars) are also approved for
treatment of CD.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):92-4 doi:10.58347/tml.2025.1730c | Show Introduction Hide Introduction
Two New Blood Tests for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Nov 23, 2026 (Issue 1768)
Diagnostics). Other FDA-cleared blood
tests for AD biomarkers are listed in Table 1.1,2 The amyloid
beta ...
Two new blood tests for biomarkers that correlate with
brain amyloid beta pathology have been cleared by the
FDA to aid in the diagnosis of Alzheimer's disease (AD):
Elecsys Phospho-Tau (217P) Plasma assay (Roche) and
PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood
tests for AD biomarkers are listed in Table 1. The amyloid
beta-directed antibodies lecanemab (Leqembi, and others)
and donanemab (Kisunla) are available for treatment of AD
in patients with mild cognitive impairment or mild dementia
who have confirmed brain amyloid pathology.
Med Lett Drugs Ther. 2026 Nov 23;68(1768):185-6 doi:10.58347/tml.2026.1768a | Show Introduction Hide Introduction
In Brief: Safety of Quinine
The Medical Letter on Drugs and Therapeutics • Nov 01, 2010 (Issue 1350)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issue 1350)
November 1, 2010 ...
Qualaquin, the only formulation of quinine sulfate available in the US, is approved only for treatment of uncomplicated malaria, but most prescriptions for its use are written for treatment or prevention of nocturnal leg cramps. The FDA recently issued a warning about its safety.Between April 2005 and October 2008, 38 cases of serious or life-threatening adverse effects of quinine were reported to the FDA. Twenty-one of these patients had thrombocytopenia and required hospitalization. Two deaths were reported: one from hemolysis and the other from thrombotic thrombocytopenic purpura (TTP)....
In Brief: Nesiritide (Natrecor)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011 (Issue 1377)
use in the broad population of
patients with acute heart failure.”1 The editorialist
lamented ...
A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001 (conditionally approved by Health Canada in 2007) for relief of dyspnea in patients with acutely decompensated heart failure. The authors of the recent clinical trial concluded: "On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure."1 The editorialist lamented the inadequacy of the data that had led to...
In Brief: Severe Hypersensitivity Reactions with Rolapitant IV Emulsion (Varubi)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
that the IV emulsion formulation of
the substance P/neurokinin 1 (NK1) receptor antagonist
rolapitant ...
The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity reactions including anaphylaxis and anaphylactic shock.1 Rolapitant was approved by the FDA as an oral tablet in 2015 for adjunctive prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults2; the IV emulsion formulation of the drug was approved for the same indication in 2017.The reported hypersensitivity reactions occurred during or shortly after infusion of...
Desmopressin for Nocturnal Enuresis
The Medical Letter on Drugs and Therapeutics • Apr 20, 1990 (Issue 816)
spontaneously in about 15% each year after that. The incidence of nocturnal enuresis in adults is less than 1 ...
Desmopressin acetate (DDAVP -Rorer), a synthetic analog of the natural human antidiuretic hormone arginine vasopressin, was recently approved by the US Food and Drug Administration for treatment of primary nocturnal enuresis. DDAVP Nasal Spray, which is similar to an intranasal solution that has been available in the USA for treatment of central diabetes insipidus (Medical Letter, 20:26, 1978), will be used for the new indication.
Interferon Beta-1a for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996 (Issue 979)
effects (R Cirelli et al, Clin Immunother, 5 suppl 1:22, 1996).
CLINICAL TRIALS — A multicenter ...
Interferon β-1a (Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a (Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Arbutamine for Stress Testing
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998 (Issue 1019)
system in pharmacologic stress testing.
MECHANISM OF ACTION — Arbutamine is a beta
1
- and beta
2 ...
Myocardial perfusion imaging and stress echocardiography in patients who cannot exercise may require use of drugs. Arbutamine (GenESA - Gensia Automedics), a potent synthetic sympathomimetic, has recently been approved by the FDA for use with a computerized drug-delivery system in pharmacologic stress testing.
Temozolomide for Refractory Anaplastic Astrocytoma
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999 (Issue 1068)
crosses the
blood-brain barrier. The drug has a mean elimination half-life of 1.8 hours (LA Hammond et al ...
Temozolomide has received accelerated approval from the FDA for oral treatment of adults with anaplastic astrocytoma that has relapsed after treatment with a nitrosourea (lomustine or carmustine) and procarbazine.
Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010 (Issue 1344)
antibiotics offer the advantage
of high airway concentrations while minimizing
systemic side effects.1 ...
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
